Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Combs, Stephanie E, Rieken, Stefan, Wick, Wolfgang, Abdollahi, Amir, von Deimling, Andreas, Debus, Jürgen, Hartmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199258/
https://www.ncbi.nlm.nih.gov/pubmed/21910919
http://dx.doi.org/10.1186/1748-717X-6-115
_version_ 1782214551121428480
author Combs, Stephanie E
Rieken, Stefan
Wick, Wolfgang
Abdollahi, Amir
von Deimling, Andreas
Debus, Jürgen
Hartmann, Christian
author_facet Combs, Stephanie E
Rieken, Stefan
Wick, Wolfgang
Abdollahi, Amir
von Deimling, Andreas
Debus, Jürgen
Hartmann, Christian
author_sort Combs, Stephanie E
collection PubMed
description A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were significantly associated with increased overall survival.
format Online
Article
Text
id pubmed-3199258
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31992582011-10-24 Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? Combs, Stephanie E Rieken, Stefan Wick, Wolfgang Abdollahi, Amir von Deimling, Andreas Debus, Jürgen Hartmann, Christian Radiat Oncol Short Report A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were significantly associated with increased overall survival. BioMed Central 2011-09-13 /pmc/articles/PMC3199258/ /pubmed/21910919 http://dx.doi.org/10.1186/1748-717X-6-115 Text en Copyright ©2011 Combs et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Combs, Stephanie E
Rieken, Stefan
Wick, Wolfgang
Abdollahi, Amir
von Deimling, Andreas
Debus, Jürgen
Hartmann, Christian
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title_full Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title_fullStr Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title_full_unstemmed Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title_short Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
title_sort prognostic significance of idh-1 and mgmt in patients with glioblastoma: one step forward, and one step back?
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199258/
https://www.ncbi.nlm.nih.gov/pubmed/21910919
http://dx.doi.org/10.1186/1748-717X-6-115
work_keys_str_mv AT combsstephaniee prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT riekenstefan prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT wickwolfgang prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT abdollahiamir prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT vondeimlingandreas prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT debusjurgen prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback
AT hartmannchristian prognosticsignificanceofidh1andmgmtinpatientswithglioblastomaonestepforwardandonestepback

Ejemplares similares